Fluorinated Lipid Nanoparticles for Gene Delivery and Diagnostics
The formulation of drug nanocarriers has attracted increasing attention over the last decades. In particular, the possibility to combine
therapeutic and imaging functionalities in a single nanoplatform (theranostic) has been widel...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CodeSphere
CodeSphere Discovering Therapeutic Nanoparticles by Molecu...
150K€
Cerrado
PID2021-124247OB-C22
TRANSPORTADORES DE ADN/ARN DE NUEVA GENERACION:CAPSIDES MOLE...
85K€
Cerrado
PNANOMED
Personalized Nanomedicines for Leukemia Patients
1M€
Cerrado
JCI-2009-04950
Nanomaterials for drug delivery, gene delivery and imaging
101K€
Cerrado
CTQ2008-02796
SINTESIS DE NANOSISTEMAS DENDRITICOS PARA APLICACIONES EN BI...
113K€
Cerrado
BES-2010-030593
MODIFICACION DE CAPSIDAS VIRICAS POR INGENIERIA DE PROTEINAS...
43K€
Cerrado
Información proyecto FluoNeeD
Duración del proyecto: 40 meses
Fecha Inicio: 2023-04-28
Fecha Fin: 2026-08-31
Líder del proyecto
POLITECNICO DI MILANO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
212K€
Descripción del proyecto
The formulation of drug nanocarriers has attracted increasing attention over the last decades. In particular, the possibility to combine
therapeutic and imaging functionalities in a single nanoplatform (theranostic) has been widely explored to advance therapeutic
approaches and promote the transition from conventional medicine to personalized medicine.
Drug nanocarriers, holding the potential to produce a revolution in medicine, are lipid nanoparticles (LNPs) for gene delivery. They
have proven versatility and efficacy even though today it is still not possible to predict and control their cellular uptake and targeted
delivery. One of the main unmet challenges of LNP formulations is increasing their cellular uptake and gene release into the cytosol.
Currently, it is possible to follow the fate of LNPs after administration only with the addition of labels (e.g., fluorophore) or specific
ribonucleic acid (RNA) sequence encoding for fluorescent protein. This results in the lack of possibility to follow the fate of LNPs once
administered in vivo with a non-invasive imaging technique. Theranostic strategies to deliver RNA and simultaneous imaging of
target organs is an important unmet goal.
Recently, it has been demonstrated that fluorination of components in gene delivery vehicles strongly improved their cellular uptake
and, most importantly, their gene endosomal escape. The fluorination strategies investigated so far use either -CF3 groups or long
linear perfluoroalkyl chains, but a tailored design of the fluorinated group could also endow the nanocarrier with excellent imaging
functions. In this context, FluoNeeD strategy is to tailor fluorination of LNPs in order to: (i) improve their therapeutic efficacy by
enhancing LNP cellular uptake and promoting gene endosomal escape; (ii) render LNPs trackable in vivo by 19F-MRI and in vitro/ex vivo by Raman microscopy.